Last reviewed 2026-04-22 · How we verify

Droperidol Injectable Product

Mercy Health Ohio · Phase 3 active Small molecule

Droperidol Injectable Product is a Butyrophenone antipsychotic Small molecule drug developed by Mercy Health Ohio. It is currently in Phase 3 development for Acute agitation and anxiety, Postoperative nausea and vomiting (PONV), Chemotherapy-induced nausea and vomiting (CINV). Also known as: Inapsine.

Droperidol is a butyrophenone antipsychotic that blocks dopamine receptors in the central nervous system, reducing agitation and providing antiemetic effects.

Droperidol is a butyrophenone antipsychotic that blocks dopamine receptors in the central nervous system, reducing agitation and providing antiemetic effects. Used for Acute agitation and anxiety, Postoperative nausea and vomiting (PONV), Chemotherapy-induced nausea and vomiting (CINV).

Likelihood of approval

55.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Droperidol Injectable Product
Also known as	Inapsine
Sponsor	Mercy Health Ohio
Drug class	Butyrophenone antipsychotic
Target	Dopamine D2 receptor
Modality	Small molecule
Therapeutic area	Psychiatry / Acute Care
Phase	Phase 3

Mechanism of action

Droperidol antagonizes dopamine D2 receptors, which suppresses psychomotor agitation and provides antiemetic activity through effects on the chemoreceptor trigger zone. It also has some alpha-adrenergic blocking properties. The drug is primarily used for acute agitation and postoperative nausea and vomiting in clinical settings.

Approved indications

Acute agitation and anxiety
Postoperative nausea and vomiting (PONV)
Chemotherapy-induced nausea and vomiting (CINV)

Common side effects

QT prolongation
Dystonia
Akathisia
Sedation
Hypotension
Tachycardia

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Droperidol Injectable Product CI brief — competitive landscape report
Droperidol Injectable Product updates RSS · CI watch RSS
Mercy Health Ohio portfolio CI

Frequently asked questions about Droperidol Injectable Product

What is Droperidol Injectable Product?

Droperidol Injectable Product is a Butyrophenone antipsychotic drug developed by Mercy Health Ohio, indicated for Acute agitation and anxiety, Postoperative nausea and vomiting (PONV), Chemotherapy-induced nausea and vomiting (CINV).

How does Droperidol Injectable Product work?

Droperidol is a butyrophenone antipsychotic that blocks dopamine receptors in the central nervous system, reducing agitation and providing antiemetic effects.

What is Droperidol Injectable Product used for?

Droperidol Injectable Product is indicated for Acute agitation and anxiety, Postoperative nausea and vomiting (PONV), Chemotherapy-induced nausea and vomiting (CINV).

Who makes Droperidol Injectable Product?

Droperidol Injectable Product is developed by Mercy Health Ohio (see full Mercy Health Ohio pipeline at /company/mercy-health-ohio).

Is Droperidol Injectable Product also known as anything else?

Droperidol Injectable Product is also known as Inapsine.

What drug class is Droperidol Injectable Product in?

Droperidol Injectable Product belongs to the Butyrophenone antipsychotic class. See all Butyrophenone antipsychotic drugs at /class/butyrophenone-antipsychotic.

What development phase is Droperidol Injectable Product in?

Droperidol Injectable Product is in Phase 3.

What are the side effects of Droperidol Injectable Product?

Common side effects of Droperidol Injectable Product include QT prolongation, Dystonia, Akathisia, Sedation, Hypotension, Tachycardia.

What does Droperidol Injectable Product target?

Droperidol Injectable Product targets Dopamine D2 receptor and is a Butyrophenone antipsychotic.

Drug class: All Butyrophenone antipsychotic drugs
Target: All drugs targeting Dopamine D2 receptor
Manufacturer: Mercy Health Ohio — full pipeline
Therapeutic area: All drugs in Psychiatry / Acute Care
Indication: Drugs for Acute agitation and anxiety
Indication: Drugs for Postoperative nausea and vomiting (PONV)
Indication: Drugs for Chemotherapy-induced nausea and vomiting (CINV)
Also known as: Inapsine

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing